Population Pharmacokinetic Pharmacodynamic Modeling of Caffeine Using Visual Analogue Scales

Rebecca N. Burns, Ayyappa Chaturvedula, David C. Turner, Hailing Zhang, Chad M. Van Den Berg

Center for Pharmacometrics, Mercer University, Atlanta, USA.
Department of Pharmaceutical Sciences, Mercer Uni-versity, Atlanta, USA.
Department of Pharmacy Practice, Mercer University, Atlanta, USA.

DOI: 10.4236/pp.2014.54054                

Abstract

Caffeine is a commonly ingested psychoactive substance which affects alertness and cognition. A clinical study was conducted to determine the effect of orally ingested caffeine on visual analogue scale (VAS) responses in healthy, moderate caffeine-consuming volunteers through the use of population pharmacokinetic-pharmacodynamic (PK-PD) modeling. Twelve subjects were recruited for a three-period cross-over study which utilized caffeine containing beverages. Each visit included 8-hour blood plasma and VAS response collection for PK and PD assessment respectively. The VAS used in the study, also called the caffeine analog scale, has been previously validated for caffeine. Population PK-PD modeling was conducted with NONMEM 7.2. Simultaneous and sequential modeling of PK-PD was attempted. Final model selection was based on parameter estimate precision, diagnostic plots, and visual predictive check (VPC) plots. Results showed that a one-compartment open model with first-order absorption and elimination best described the pharmacokinetics of caffeine. Sequential PK-PD modeling was successful and an effect compartment model with linear slope and baseline parameter best described caffeine pharmacodynamics. Diagnostic plots showed no major bias and VPC plots showed agreement between observations and predictions. The model was able to link VAS responses to caffeine concentration in healthy volunteers and may be useful in clinical trial simulations and design.

Keywords

Caffeine; Population Pharmacokinetics; Population Pharmacodynamics; NONMEM^®; Visual Analogue Scale

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Fredholm, B.B., Bättig, K., Holmén, J., Nehlig, A. and Zvartau, E.E. (1999) Actions of Caffeine in the Brain with Special Reference to Factors That Contribute to Its Widespread Use. Pharmacological Reviews, 51, 83-133.
[2]	Magkos, F. and Kavouras, S.A. (2005) Caffeine Use in Sports, Pharmacokinetics in Man, and Cellular Mechanisms of Action. Critical Reviews in Food Science and Nutrition, 45, 535-562. http://dx.doi.org/10.1080/1040-830491379245
[3]	Seng, K.Y., Teo, W.L., Fun, C.Y., Law, Y.L. and Lim, C.L. (2010) Interrelations between Plasma Caffeine Concentrations and Neurobehavioural Effects in Healthy Volunteers: Model Analysis Using NONMEM. Biopharmaceutics & Drug Disposition, 31, 316-330.
[4]	Lieberman, H.R., Wurtman, R.J., Emde, G.G. and Coviella, I.L. (1987) The Effects of Caffeine and Aspirin on Mood and Performance. Journal of Clinical Psychopharmacology, 7, 315-320. http://dx.doi.org/10.1097/00004714-198710000-00004
[5]	Shi, J., Benowitz, N.L., Denaro, C.P. and Sheiner, L.B. (1993) Pharmacokinetic-Pharmacodynamic Modeling of Caffeine: Tolerance to Pressor Effects. ClinPharmacolTher, 53, 6-14. http://dx.doi.org/10.1038/clpt.1993.3
[6]	Leathwood, P.D. and Pollet, P. (1982-1983) Diet-Induced Mood Changes in Normal Populations. Journal of Psychiatric Research, 17, 147-154. http://dx.doi.org/10.1016/0022-3956(82)90016-4
[7]	Alkaysi, H.N., Salem, M.S. and El-Sayed, Y.M. (1988) High Performance Liquid Chromatographic Analysis of Caffeine Concentrations in Plasma and Saliva. Journal of Clinical Pharmacy and Therapeutics, 13, 109-115. http://dx.doi.org/10.1111/j.1365-2710.1988.tb00165.x
[8]	Beal, S., Boeckmann, A. and Sheiner, L. (1989-2009) NONMEM Users Guides. Icon Development Solutions, Ellicott City.
[9]	Holford, N. (2005) The Visual Predictice Check-Superioirty to Standard Diagnositc (Rorschach) Plots.
[10]	Seng, K.Y., Fun, C.Y., Law, Y.L., Lim, W.M., Fan, W. and Lim, C.L. (2009) Population Pharmacokinetics of Caffeine in Healthy Male Adults Using Mixed-Effects Models. Journal of Clinical Pharmacy and Therapeutics, 34, 103-114. http://dx.doi.org/10.1111/j.1365-2710.2008.00976.x
[11]	Zhang, L., Beal, S.L. and Sheiner, L.B. (2003) Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best-Case Performance. Journal of Pharmacokinetics and Pharmacodynamics, 30, 387-404. http://dx.doi.org/a10.1023/B:JOPA.0000012998.04442.1f